Literature DB >> 28937375

Superficial CD34-positive fibroblastic tumor: A new entity; case report and review of literature.

Neelam Sood1, Binit Kumar Khandelia1.   

Abstract

Earlier, categorized under low grade malignant fibrous histiocytoma and low grade sarcomas, 'superficial CD34 positive fibroblastic tumor', a newly proposed entity, is a low grade mesenchymal tumor of intermediate malignant potential. Morphological features include monomorphic neoplastic spindle cells arranged in a fascicular to storiform pattern along with sheets of pleomorphic epithelioid cells, and multinucleated giant cells with glassy cytoplasm. Diffuse vimentin and characteristic diffuse CD34 positivity is seen in all cases with few showing focal cytokeratin expression. Rest of the melanocytic and mesenchymal markers are negative. Herein, we present a case of superficial CD34-positive fibroblastic tumor in arm swelling of a 16-year-old female. Differential diagnosis of the same on the basis of morphology as well as immunohistochemistry has also been discussed. This is the first case reported from India to the best of our knowledge.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28937375     DOI: 10.4103/IJPM.IJPM_589_16

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  3 in total

1.  Superficial CD34-positive fibroblastic tumor: report of two cases and review of literature.

Authors:  Xu Mao; Ying-Ying Sun; Ming-Liang Deng; Tao Ma; Lan Yu
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

2.  Superficial CD34-Positive Fibroblastic Tumor: Report of an Extremely Rare Entity.

Authors:  Ebru Zemheri; Ayşe Serap Karadag; İsmail Yılmaz
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

3.  Perianal superficial CD34-positive fibroblastic tumor: A case report.

Authors:  Chen-Yan Long; Tao-Li Wang
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.